Suppr超能文献

药物-药物相互作用和出院时的处方适宜性:COVID-19 患者的经验。

Drug-Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients.

机构信息

Gestione Ambulatoriale Politerapie (GAP) Outpatient Clinic, ASST Fatebenefratelli-Sacco University Hospital, Milan, Italy.

Unit of Clinical Pharmacology, ASST Fatebenefratelli-Sacco University Hospital, Milan, Italy.

出版信息

Drugs Aging. 2021 Apr;38(4):341-346. doi: 10.1007/s40266-021-00840-y. Epub 2021 Mar 1.

Abstract

BACKGROUND

Patients with coronavirus disease 2019 (COVID-19) are often elderly, with comorbidities, and receiving polypharmacy, all of which are known factors for potentially severe drug-drug interactions (DDIs) and the prescription of potentially inappropriate medications (PIMs).

OBJECTIVE

The aim of this study was to assess the risk of DDIs and PIMs in COVID-19 patients at hospital discharge.

METHOD

Patients with a proven diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who were hospitalized between 21 February and 30 April 2020, treated with at least two drugs, and with available information regarding pharmacological treatments upon admission and at discharge were considered. The appropriateness of drug prescriptions was assessed using INTERcheck.

RESULTS

A significant increase in the prescription of proton pump inhibitors and heparins was found when comparing admission with hospital discharge (from 24 to 33% [p < 0.05] and from 1 to 17% [p < 0.01], respectively). The increased prescription of heparins at discharge resulted in a highly significant increase in the potentially severe DDIs mediated by this class of drugs. 51% of COVID-19 patients aged > 65 years had at least one PIM upon admission, with an insignificant increment at discharge (58%).

CONCLUSION

An increased number of prescribed drugs was observed in COVID-19 patients discharged from our hospital. The addition of heparins is appropriate according to the current literature, while the use of proton pump inhibitors is more controversial. Particular attention should be paid to the risk of bleeding complications linked to heparin-based DDIs.

摘要

背景

患有 2019 年冠状病毒病(COVID-19)的患者通常为老年人,伴有合并症,并接受多种药物治疗,这些都是潜在严重药物相互作用(DDI)和潜在不适当药物(PIM)处方的已知因素。

目的

本研究旨在评估 COVID-19 患者出院时发生药物相互作用和潜在不适当药物的风险。

方法

考虑患有经证实的严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染的患者,这些患者在 2020 年 2 月 21 日至 4 月 30 日之间住院,接受至少两种药物治疗,并且在入院和出院时可获得有关药物治疗的信息。使用 INTERcheck 评估药物处方的适宜性。

结果

与入院时相比,出院时质子泵抑制剂和肝素的处方显著增加(分别从 24%增加到 33%[p<0.05]和从 1%增加到 17%[p<0.01])。出院时肝素处方的增加导致该类药物介导的潜在严重药物相互作用显著增加。51%的>65 岁 COVID-19 患者入院时至少有一种 PIM,出院时无明显增加(58%)。

结论

从我们医院出院的 COVID-19 患者的处方药物数量有所增加。根据目前的文献,肝素的添加是合理的,而质子泵抑制剂的使用更具争议性。应特别注意与肝素类药物相互作用相关的出血并发症风险。

相似文献

引用本文的文献

本文引用的文献

4
Aging in COVID-19: Vulnerability, immunity and intervention.COVID-19 相关衰老问题:脆弱性、免疫与干预。
Ageing Res Rev. 2021 Jan;65:101205. doi: 10.1016/j.arr.2020.101205. Epub 2020 Oct 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验